Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1

PHASE3CompletedINTERVENTIONAL
Enrollment

1,554

Participants

Timeline

Start Date

June 30, 1997

Study Completion Date

August 31, 2000

Conditions
HIV InfectionsPregnancy
Interventions
DRUG

ZDV Short (mother)-Short (infant): Comparison of zidovudine durations

Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)

DRUG

ZDV Short (mother)-Long (infant): Comparison of zidovudine durations

Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)

DRUG

ZDV Long (mother)-Short (infant): Comparison of zidovudine durations

Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)

DRUG

ZDV Long (mother)-Long (infant): Comparison of zidovudine durations

Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)

Trial Locations (1)

50200

Phpt - Ird 174, Chiang Mai

All Listed Sponsors
collaborator

Harvard School of Public Health (HSPH)

OTHER

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Institut de Recherche pour le Developpement

OTHER_GOV

NCT00386230 - Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1 | Biotech Hunter | Biotech Hunter